Noxopham Annual Report 2025

Annual Report 2025 49 Other information The directors are responsible for the other information. The other information comprises the information included in the Group’s annual report for the year ended 30 June 2025 but does not include the financial report and our auditor’s report thereon. Our opinion on the financial report does not cover the other information and accordingly we do not express any form of assurance conclusion thereon. In connection with our audit of the financial report, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial report or our knowledge obtained in the audit or otherwise appears to be materially misstated. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard. Responsibilities of the directors for the financial report The directors of the Company are responsible for the preparation of: — the financial report (other than the consolidated entity disclosure statement) that gives a true and fair view in accordance with Australian Accounting Standards and the Corporations Act 2001; and — the consolidated entity disclosure statement that is true and correct in accordance with the Corporations Act 2001, and for such internal control as the directors determine is necessary to enable the preparation of: — the financial report (other than the consolidated entity disclosure statement) that gives a true and fair view and is free from material misstatement, whether due to fraud or error; and associated to the host liability and additionally a value associated with the embedded derivative which is accounted for at fair value through the statement of profit or loss and other comprehensive income. As part of the convertible note issue, 520,000 share options were also issued to the Noteholders. The accounting for the convertible notes and related derivatives is a key audit matter due to the complex nature, including judgemental estimates used in determining the valuation of the convertible notes at initial recognition, and at year end. appropriately recognised as a hybrid arrangement. — Utilised an external valuation specialist to assist with assessing the reasonableness of the valuation method and model used to value the embedded derivative and options including the key inputs into the model and the resulting valuation amounts recognised by management; — Assessed the accuracy of the calculation of the interest expense; and — Involved our technical accounting specialists to assist in considering the appropriateness of the adopted accounting treatment. We also considered the adequacy of the Group’s disclosures in the notes to the financial report.

RkJQdWJsaXNoZXIy MjE2NDg3